Research institute launches tender for integrated multi-omic analysis
Research body seeks external provider for complex multi-omic analysis to support advanced oncology and immuno-oncology studies.
Research body seeks external provider for complex multi-omic analysis to support advanced oncology and immuno-oncology studies.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.
Institut Bergonié is seeking an external partner to deliver integrated multi-omic analysis across a range of biological samples, in support of its oncology and immuno-oncology research projects. The new contract signals growing demand in the research sector for specialist providers capable of handling complex, data-heavy studies rather than relying solely on in-house laboratory capacity.
The contract notice, published on 30th April 2026, describes a plan to outsource integrated multi-omic analyses of various biological samples for research at Institut Bergonié. Rather than investing in additional internal platforms and staff, the institute intends to buy in a comprehensive service that spans multiple molecular layers.
Multi-omic work brings together different types of biological information from the same samples. For cancer and immuno-oncology research, that typically means combining data that describe the tumour itself with signals from the surrounding immune environment. The notice makes clear that this integration is central to the requirement: the institute is not just commissioning individual tests, but a service that can link results across modalities to support its project portfolio.
The reference to “various biological samples” suggests the contract is designed to cope with a wide range of material generated by research studies, from solid tissues to blood-derived samples, although the notice does not specify exact sample types. What is explicit is the application focus: the analyses must serve oncology and immuno-oncology projects run at Institut Bergonié, anchoring the work firmly in cancer research rather than general-purpose diagnostics.
By outsourcing, the buyer is aligning with a broader shift in the sector towards flexible access to high-end omics capabilities. For suppliers, this creates an opening for laboratories and consortia that can combine advanced instrumentation, robust workflows and bioinformatic interpretation into an integrated offer tailored to cancer research teams.
The Bergonié tender sits within a dense wave of recent procurements that are reshaping how hospitals and universities across Europe access advanced molecular analysis. Many of these focus on building local infrastructure, while others, like Bergonié’s, prioritise external services.
On the infrastructure side, a cluster of notices is pushing spatial and multiplexed technologies into mainstream research settings:
Taken together, these procurements show research and clinical centres investing across the full spectrum of omics technologies: from spatial platforms and high-content imaging to genomics and transcriptomics. Some are equipping internal facilities; others are building pathways to external expertise. In that landscape, the Bergonié contract stands out as a deliberate choice to concentrate on an integrated service model for complex multi-omic analysis.
Alongside equipment purchases, there is steady growth in tenders that, like Institut Bergonié’s, focus on buying omics as a service. These notices emphasise data delivery and interpretation, with laboratory capacity largely sitting outside the host institution.
In March 2026, Maynooth University launched a competition titled Spatial Transcriptomics Services, seeking providers for spatial and single cell transcriptomic analysis of human tissues, with the goal of identifying disease drivers and drug resistance targets. Here, as in Bergonié’s tender, the emphasis is on high-value analytical insight rather than ownership of particular instruments.
Other recent examples include:
Across these procurements, buyers are taking different routes to similar goals: robust, scalable access to sophisticated analysis. Some institutions are building complete in-house pipelines, including installation, training and long-term maintenance of high-end instruments. Others, including Institut Bergonié, are choosing to treat these capabilities as contracted services, leaning on external partners to deliver both the laboratory work and the integrated analytical outputs.
For service providers, this shifts competition away from individual technologies and towards end-to-end capability: capacity to handle diverse sample types, combine multiple omic readouts, manage quality control and return results in formats that plug directly into research workflows.
The focus on multi-omic analysis in the Bergonié tender underscores how cancer research is evolving. Traditional single-assay approaches can miss important aspects of tumour biology and immune response. Integrated multi-omic strategies, by contrast, allow research teams to relate changes across different molecular layers in the same samples.
For oncology projects, this can illuminate how tumours develop, evolve and respond to treatment. For immuno-oncology, where therapies aim to harness or redirect the immune system, multi-omic datasets help researchers understand how immune cells interact with cancer cells and with their wider microenvironment. Bringing these perspectives together in a single analytical service is what gives the Bergonié contract its strategic weight.
The similar procurements reinforce this trend. Spatial transcriptomics and proteomics tenders from institutions such as Sapienza, Uppsala and Umeå emphasise the need to see not only which molecules are present, but where they sit in the architecture of tissues. Sequencing and genomic profiling contracts from centres in Plovdiv, Lille and the Balearic Islands highlight demand for deep, high-resolution views of the genome and transcriptome. The Bergonié contract extends this trajectory by asking for integrated multi-omic analyses delivered as an outsourced service, directly tied to defined oncology and immuno-oncology research projects.
The Integrated Multi-Omic Analysis Services contract at Institut Bergonié will be one to follow for organisations active in omics services. Its emphasis on outsourcing integrated analyses for oncology and immuno-oncology mirrors a growing appetite across the research and healthcare sectors for comprehensive, service-based access to advanced molecular technologies.
Future notices will show whether more centres choose the same route, or whether they opt instead to build local platforms in-house. For now, the Bergonié procurement underlines that there is space in the market for suppliers who can provide not just individual assays, but coherent, multi-omic analysis pipelines aligned with the needs of modern cancer research.
Follow Tenderlake on LinkedIn for concise insights on public-sector tenders and emerging procurement signals.